Bris­tol My­ers vets tie up an­oth­er all-stock deal, lin­ing up clin­i­cal-stage on­col­o­gy pipeline

A hand­ful of Bris­tol My­ers Squibb vets set­ting up a fledg­ling can­cer drug de­vel­op­er have wrapped back-to-back stock deals to cre­ate a new on­col­o­gy pipeline.

Portage Biotech is helmed by CEO Ian Wal­ters and CSO Robert Kramer, and backed by three biotech en­tre­pre­neurs — UK in­vestor Jim Mel­lon, ex-Bio­haven board mem­ber De­clan Doogan and ear­ly Medi­va­tion backer Greg Bai­ley — who have whipped up a whole slate of dif­fer­ent ven­tures aimed at drug de­vel­op­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER